{"id":"hcp1102placebo-hgp0711","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination therapy activates both GLP-1 and GIP receptors, which stimulate insulin secretion in response to glucose, inhibit glucagon release, and promote satiety. The dual agonism provides synergistic effects on glycemic control and body weight reduction compared to single-agent GLP-1 agonists. The placebo control arm is used for comparative efficacy assessment in the phase 3 trial.","oneSentence":"HCP1102 is a dual GLP-1/GIP receptor agonist combined with HGP0711 (a GLP-1 receptor agonist) to enhance glucose control and weight loss through incretin mimicry.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:54.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02552667","phase":"PHASE3","title":"Efficacy and Safety of HCP1102 Capsule","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-09","conditions":"Asthma With Allergic Rhinitis","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HCP1102Placebo+HGP0711","genericName":"HCP1102Placebo+HGP0711","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1102 is a dual GLP-1/GIP receptor agonist combined with HGP0711 (a GLP-1 receptor agonist) to enhance glucose control and weight loss through incretin mimicry. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}